Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

January 8, 2024

Study Completion Date

January 8, 2024

Conditions
Cholangiocarcinoma
Interventions
COMBINATION_PRODUCT

Combination of Lonsurf® and Irinotecan

"Trifluridine/Tipiracil (Lonsurf®) and Irinotecan~* Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.~* Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose."

Trial Locations (1)

40225

Klinik für Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf

All Listed Sponsors
collaborator

Servier

INDUSTRY

lead

Heinrich-Heine University, Duesseldorf

OTHER

NCT04059562 - Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma | Biotech Hunter | Biotech Hunter